Lemon Grove
Lemon Grove
Lemon Grove, California, United States27 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients | brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder | Recruiting | Phase 2 | 2026-10-09 | NCT07646613 | |
| A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Active, not recruiting | Phase 3 | 2026-10-05 | NCT06894212 | |
| Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-28 | NCT07686263 | |
| A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT07621237 | |
| Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | NCT07227818 | |
| NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | NCT07114874 | |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT06480383 | |
| Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder | Bipolar I or II Disorder | Active, not recruiting | Phase 2 | 2026-09-23 | NCT07220460 | |
| A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 | 2026-09-17 | NCT06223360 | |
| Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT) | Smoking Cessation | Recruiting | Phase 3 | 2026-09-08 | NCT07766655 | |
| A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Not yet recruiting | Phase 2 | 2026-09-04 | NCT07772531 | |
| A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, nervous system disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 2 | 2026-09-01 | NCT07459647 | |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, bipolar I disorder, nervous system disorder | Active, not recruiting | Phase 2 | 2026-08-10 | NCT07046494 | |
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. | bipolar I disorder | Recruiting | Phase 2 | 2026-07-27 | NCT07494305 | |
| Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-07-27 | NCT07363577 | |
| A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia | Cognition Disorders, Cognitive Dysfunction, Schizophrenia Spectrum and Other Psychotic Disorders, cognitive disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 2 | 2026-06-23 | NCT07191483 | |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-06-17 | NCT06846320 | |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-06-15 | NCT07276997 | |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Body Weight, Body Weight Changes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss | Active, not recruiting | Phase 3 | 2026-04-07 | NCT07104383 | |
| A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-01-21 | NCT05026866 | |
| Randomized Withdrawal Study in Patients With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-01-12 | NCT06961968 | |
| VK2735 for Weight Management Phase 3 | Body Weight, Body Weight Changes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss | Active, not recruiting | Phase 3 | 2025-11-24 | NCT07104500 | |
| ERG Components in Schizophrenia and Bipolar Disorder Type I | Schizophrenia Spectrum and Other Psychotic Disorders, bipolar I disorder, psychiatric disorder, schizophrenia | Active, not recruiting | Not stated | 2025-08-22 | NCT03788811 | |
| Methadone Dose Monitoring With a Remote Medication Monitor | Chronic Pain, Drug Metabolism, Poor, CYP2D6-Related, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Not yet recruiting | Not stated | 2025-02-20 | NCT06837571 | |
| Assessing Concentrations of Methadone and Its Metabolites | Chemically-Induced Disorders, Narcotic-Related Disorders, Neurologic Manifestations, Opioid Use Disorder, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, opiate dependence, psychiatric disorder, substance-related disorder | Enrolling by invitation | Not stated | 2025-02-19 | NCT06835582 |